Related Experiment Video
Updated: Jan 30, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
Logan Corey1, Ana Valente1, Katrina Wade2
1Department of Obstetrics and Gynecology, Ochsner Clinic Foundation, 2700 Napoleon Avenue, New Orleans, LA 70115, USA.
Abstract:
Personalized medicine in gynecologic oncology is an evolving field. In recent years, tumor profiling and large databases such as TCGA and NCI-Match have provided us with enormous amounts of molecular data. Several therapies that capitalize on novel genetic and immune discoveries including VEGF inhibitors, PARP inhibitors, and cancer vaccinations are discussed in this article. Additionally, we have seen direct to consumer marketing play an important role in cancer care and prevention as patients have increased ability to access genetic testing. This presents a unique challenge to gynecologic oncology providers as we learn to navigate the world of personalized medicine.
Insights
Personalized medicine is advancing gynecologic oncology with new genetic and immune therapies. Increased patient access to genetic testing presents both opportunities and challenges for providers navigating this evolving field.
Area of Science:
- Gynecologic Oncology
- Personalized Medicine
- Molecular Oncology
Background:
- Personalized medicine is rapidly evolving in gynecologic oncology.
- Large-scale molecular data from tumor profiling initiatives like TCGA and NCI-Match are increasingly available.
- Direct-to-consumer genetic testing is impacting cancer care and prevention strategies.
Purpose of the Study:
- To review current advancements in personalized medicine for gynecologic cancers.
- To discuss novel therapies based on genetic and immune discoveries.
- To highlight the challenges and opportunities presented by increased patient access to genetic testing.
Main Methods:
- Literature review of recent advancements in gynecologic oncology.
- Discussion of targeted therapies including VEGF inhibitors, PARP inhibitors, and cancer vaccines.
- Analysis of the impact of direct-to-consumer genetic testing on clinical practice.
Main Results:
- Several novel targeted therapies are emerging, including VEGF inhibitors, PARP inhibitors, and cancer vaccines.
- Patients have greater access to genetic testing, influencing their engagement in cancer care.
- The integration of personalized medicine requires adaptation by gynecologic oncology providers.
Conclusions:
- Personalized medicine offers significant potential to improve outcomes in gynecologic oncology.
- Navigating the complexities of molecular data and patient-driven genetic testing is crucial for providers.
- Future directions involve integrating these advancements into routine clinical practice.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics
Personal Identity
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Self-Report Tests of Personality
Personal Protective Equipment

